Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces its purchase of the product Surpass® (1% diclofenac sodium) from IDEXX Laboratories, Inc. Effective immediately, BIVI is marketing the product through the existing animal health distribution channels and veterinarians.

“We are excited to add Surpass and its technical support personnel to our equine portfolio and team,” says Matt Musselman, Director, Equine Segment for BIVI.  “We are committed to providing veterinarians with unique and innovative products and superior technical equine service.”

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit www.bi-vetmedica.com.